Vaccine may improve breast cancer treatment outcomes

Vaccine may improve breast cancer treatment outcomes

Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen receptor-negative (HER2-positive, ER-negative) breast cancer and has shown encouraging results in a recent pilot study. The study combined the HER2-targeting dendritic cell vaccines with standard chemotherapy, demonstrating both safety and positive …

Dendritic cell vaccine strategy may improve breast cancer treatment outcomes

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen receptor-negative (HER2-positive, ER-negative) breast cancer and has shown encouraging results in a recent pilot study.

Chemoprevention use after TNBC ‘may be reasonable’

By Lynda Williams, medwireNews ReportermedwireNews: Research indicates that women with triple-negative breast cancer might benefit from low-dose tamoxifen to reduce the risk of recurrent or new primary disease.This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.Read the full story on the L’Institut Servier websiteImage credit: © Crystal light / Stock.adobe.com The post Chemoprevention use a…

Evolving Treatment Strategies in Early HER2+ Breast Cancer

Experts discuss how, nearly half of patients diagnoses with HER-2 positive metastatic brain cancer do develop brain metastasis. It is thought that larger molecule treatments such as the monoclonal antibodies likely do not cross an intact blood brain barrier which is often why patients develop brain metastases

Vaccine Enhances Chemotherapy Response in HER2+ Breast Cancer

Researchers at Moffitt Cancer Center have identified a promising new approach for improving treatment outcomes in HER2-positive, ER-negative breast cancer. Their study, published in npj Breast Cancer, demonstrates that a dendritic cell vaccine targeting the HER2 protein enhances the immune system’s ability to attack tumors and increases chemotherapy effectiveness. The pilot study involved 30 patients with stage 2 and stage 3 HER2-positive, ER-ne…